Novo Holdings is expected to acquire 60% of Single Use Support, with the remaining shares being held by Danaher and the company founders.
Novo Holdings Acquires Majority Share of Single Use Support to Expand Life Science Tools, Diagnostics Portfolio
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Estimated read time
1 min read
+ There are no comments
Add yours